We are live on ! Find out more
EWM

Essex Woodlands Management Portfolio holdings

AUM $254M
1-Year Est. Return 4.59%
This Fund
S&P 500
This Quarter Est. Return
+4.89%
1 Year Est. Return
+4.59%
3 Year Est. Return
+54.96%
5 Year Est. Return
+25.37%
10 Year Est. Return
+254.56%
AUM
$640M
AUM Growth
+$254M
Cap. Flow
+$191M
Cap. Flow %
29.86%
Top 10 Hldgs %
100%
Holding
9
New
1
Increased
2
Reduced
2
Closed

Top Buys

Rank Stock Value
1
BVS icon
Bioventus
BVS
+$172M
2
MDXG icon
MiMedx Group
MDXG
+$37.6M
3
TELA icon
TELA Bio
TELA
+$1.58M

Top Sells

Rank Stock Value
1
RVNC
Revance Therapeutics, Inc.
RVNC
+$16.1M
2
AXGN icon
Axogen
AXGN
+$4.39M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MDXG icon
1
MiMedx Group
MDXG
$624M
$241M 37.64%
23,376,623
+3,896,104
+20% +$37.6M
BVS icon
2
Bioventus
BVS
$1.17B
$185M 28.89%
+12,096,702
New +$172M
RVNC
3
DELISTED
Revance Therapeutics, Inc.
RVNC
$77.1M 12.06%
2,759,950
-582,097
-17% -$16.1M
EYPT icon
4
EyePoint Inc
EYPT
$1.17B
$42.6M 6.66%
4,190,921
AXGN icon
5
Axogen
AXGN
$2.67B
$35.7M 5.57%
1,759,699
-222,189
-11% -$4.39M
VERO
6
DELISTED
Venus Concept
VERO
$29.2M 4.56%
75,260
TELA icon
7
TELA Bio
TELA
$32.3M
$23.5M 3.68%
1,580,089
+104,796
+7% +$1.58M
MNOV icon
8
MediciNova
MNOV
$65.5M
$5.58M 0.87%
1,105,941
GYRE icon
9
Gyre Therapeutics
GYRE
$706M
$396K 0.06%
10,483

Similar funds

Essex Woodlands Management's Q1 2021 Portfolio in Review

As of Q1 2021, Essex Woodlands Management held 9 positions worth $640M, up 66% from $385M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Essex Woodlands Management deployed $191M of net new capital in Q1 2021, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Bioventus: 12,096,702 shares worth $185M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Revance Therapeutics, Inc., an estimated $16.1M trimmed.

  • Essex Woodlands Management's largest Q1 2021 buy was Bioventus: 12,096,702 shares worth $185M.
  • Essex Woodlands Management added most to MiMedx Group in Q1 2021, an estimated $37.6M increase.
  • Essex Woodlands Management's biggest Q1 2021 reduction was Revance Therapeutics, Inc., cutting an estimated $16.1M.
  • Essex Woodlands Management's ten largest holdings make up 100% of its $640M portfolio in Q1 2021.
  • Essex Woodlands Management opened 1 new position and closed 0 in Q1 2021.
  • Essex Woodlands Management's portfolio value rose 66% quarter-over-quarter to $640M.

Based on Essex Woodlands Management's 13F filing for Q1 2021, filed 14 May 2021.